Abstract | BACKGROUND: METHODS: RESULTS: Median overall survival (OS) was longer in early radiotherapy group compared to deferred radiotherapy group (17.9 months vs 12.6 months; P=0.038). Progression free survival (PFS) was also improved in patients receiving early radiotherapy compared to those receiving deferred radiotherapy (4.0 months vs 3.0 months; P<0.01). Receiving tyrosine kinase inhibitor (TKI) therapy after the diagnosis of brain metastases as any line therapy improved the OS (20.0 months vs 10.7 months; P<0.01), whereas receiving TKI as first line therapy did not (17.9 months vs 15.2 months; P=0.289). CONCLUSIONS: Our study suggests that the use of deferred brain radiotherapy may resulted in inferior OS in patients with NSCLC who develop brain metastases. A prospective multi-central randomized study is imminently needed.
|
Authors | Yang Wang, Jian Fang, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiangjuan Ma, Jindi Han, Xiaoling Chen, Guangming Tian, Di Wu, Sen Han, Jieran Long |
Journal | Zhongguo fei ai za zhi = Chinese journal of lung cancer
(Zhongguo Fei Ai Za Zhi)
Vol. 19
Issue 8
Pg. 508-14
(Aug 20 2016)
ISSN: 1999-6187 [Electronic] China |
PMID | 27561799
(Publication Type: Journal Article)
|
Topics |
- Brain Neoplasms
(drug therapy, radiotherapy, secondary)
- Carcinoma, Non-Small-Cell Lung
(pathology)
- Combined Modality Therapy
- Cranial Irradiation
(adverse effects, methods)
- Female
- Humans
- Lung Neoplasms
(pathology)
- Male
- Middle Aged
- Molecular Targeted Therapy
- Time Factors
- Treatment Outcome
|